• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    6/7/23 1:31:48 PM ET
    $ALLR
    $AVTX
    $CARM
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLR alert in real time by email

    Gainers

    • Avalo Therapeutics (NASDAQ:AVTX) shares rose 17.3% to $3.53 during Wednesday's regular session. The company's market cap stands at $46.5 million.
    • Journey Medical (NASDAQ:DERM) shares rose 15.59% to $1.84. Trading volume for this security as of 13:30 EST is 55.9K, which is 228.4% of its average full-day volume over the last 100 days. The company's market cap stands at $33.3 million.
    • Societal CDMO (NASDAQ:SCTL) shares rose 15.14% to $0.9. Trading volume for Societal CDMO's stock is 81.4K as of 13:30 EST. This is 43.5% of its average full-day volume over the last 100 days. The company's market cap stands at $76.2 million.
    • Microbot Medical (NASDAQ:MBOT) stock moved upwards by 14.79% to $2.56. The current volume of 1.5 million shares is 44.6% of Microbot Medical's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $24.9 million.
    • Mereo BioPharma Group (NASDAQ:MREO) shares moved upwards by 14.78% to $1.32. Trading volume for Mereo BioPharma Group's stock is 3.3 million as of 13:30 EST. This is 194.0% of its average full-day volume over the last 100 days. The company's market cap stands at $164.9 million.
    • Oncology Institute (NASDAQ:TOI) stock rose 14.78% to $0.47. Trading volume for this security as of 13:30 EST is 289.6K, which is 108.5% of its average full-day volume over the last 100 days. The company's market cap stands at $35.4 million.

    Losers

    • PolarityTE (NASDAQ:PTE) shares declined by 43.1% to $0.25 during Wednesday's regular session. PolarityTE's stock is trading at a volume of 2.0 million shares as of 13:30 EST. This is 2960.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.8 million.
    • Vaxart (NASDAQ:VXRT) stock decreased by 28.3% to $0.89. As of 13:30 EST, this security is trading at a volume of 8.3 million shares, making up 547.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $120.5 million.
    • Allarity Therapeutics (NASDAQ:ALLR) stock decreased by 20.05% to $0.19. Trading volume for this security as of 13:30 EST is 3.0 million, which is 91.7% of its average full-day volume over the last 100 days. The company's market cap stands at $3.5 million.
    • NewAmsterdam Pharma (NASDAQ:NAMS) stock decreased by 16.16% to $11.55. Trading volume for NewAmsterdam Pharma's stock is 429.0K as of 13:30 EST. This is 1273.7% of its average full-day volume over the last 100 days. The company's market cap stands at $944.4 million.
    • CARISMA Therapeutics (NASDAQ:CARM) stock fell 16.01% to $6.09. Trading volume for CARISMA Therapeutics's stock is 289.3K as of 13:30 EST. This is 160.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $245.1 million.
    • HTG Molecular Diagnostics (NASDAQ:HTGM) shares decreased by 13.78% to $0.76. Trading volume for this security as of 13:30 EST is 449.6K, which is 218.1% of its average full-day volume over the last 100 days. The company's market cap stands at $1.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLR
    $AVTX
    $CARM
    $DERM

    CompanyDatePrice TargetRatingAnalyst
    Mereo BioPharma Group plc
    $MREO
    3/23/2026Overweight → Neutral
    Analyst
    NewAmsterdam Pharma Company N.V.
    $NAMS
    3/18/2026$57.00Buy
    Truist
    Microbot Medical Inc.
    $MBOT
    2/10/2026$5.00Buy
    B. Riley Securities
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Mereo BioPharma Group plc
    $MREO
    12/30/2025$0.50Buy → Hold
    Jefferies
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Microbot Medical Inc.
    $MBOT
    12/3/2025$5.50Buy
    Roth Capital
    The Oncology Institute Inc.
    $TOI
    11/25/2025$5.00Buy
    Needham
    More analyst ratings

    $ALLR
    $AVTX
    $CARM
    $DERM
    SEC Filings

    View All

    SEC Form 144 filed by Avalo Therapeutics Inc.

    144 - Avalo Therapeutics, Inc. (0001534120) (Subject)

    4/1/26 4:48:44 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.

    SCHEDULE 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    4/1/26 1:02:57 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    4/1/26 8:54:39 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Madden Martin J.

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    4/3/26 4:30:41 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Stockburger Aileen Ptucha

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    4/3/26 4:30:43 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Wenderow Tal Baruch

    4 - Microbot Medical Inc. (0000883975) (Issuer)

    4/3/26 4:30:40 PM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mereo BioPharma downgraded by Analyst

    Analyst downgraded Mereo BioPharma from Overweight to Neutral

    3/23/26 8:27:06 AM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on NewAmsterdam Pharma with a new price target

    Truist initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $57.00

    3/18/26 3:54:27 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Microbot Medical with a new price target

    B. Riley Securities initiated coverage of Microbot Medical with a rating of Buy and set a new price target of $5.00

    2/10/26 8:01:31 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $1,225,101 worth of shares (398,985 units at $3.07), increasing direct ownership by 4% to 10,251,929 units (SEC Form 4)

    4 - Oncology Institute, Inc. (0001799191) (Issuer)

    3/17/26 7:40:00 PM ET
    $TOI
    Medical/Nursing Services
    Health Care

    Director Watson W. Mark bought $8,185 worth of shares (20,000 units at $0.41), increasing direct ownership by 19% to 124,125 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    12/5/25 5:46:47 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Heron Elaine J bought $15,921 worth of shares (40,000 units at $0.40), increasing direct ownership by 71% to 96,566 units (SEC Form 4)

    4 - Vaxart, Inc. (0000072444) (Issuer)

    11/21/25 1:21:51 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

    Issued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, March 27, 2026 /CNW/ -- Equity-Insider.com News Commentary – The traditional hospital model is undergoing a massive structural shift. Outpatient clinics and ambulatory services are quickly becoming the primary growth engines for the entire U.S. healthcare sector. In fact, Ernst & Young's 2026 outlook confirms that these accessible, lower-acuity care segments are attracting the heaviest strategic capital allocations as health systems realign their infrastructure[1]. This powerful momentum is accelerating across the medical technology space. Recent data from NVIDIA's 2026 healthcare survey shows that 70% of organizations are now ac

    3/27/26 10:15:00 AM ET
    $CLOV
    $LIVN
    $MBOT
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Biological Products (No Diagnostic Substances)

    Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®'s LIBERTY® Endovascular Robotic System

    World's first robotic Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) and robotic Y-90 radioembolization mapping for liver cancer are among the robotic cases performed using the LIBERTY System, demonstrating system adoption across multiple case types ATLANTA and HINGHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Emory Healthcare has successfully completed robotic peripheral endovascular procedures — minimally invasive treatments for certain vascular conditions — using Microbot Medical's (NASDAQ:MBOT) LIBERTY® Endovascular Robotic System. Microbot believes that the application of the single-use robotic system can expand patient access to high-quality care. Emory

    3/26/26 8:30:00 AM ET
    $MBOT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Appoints Kim Tzoumakas to Board of Directors

    CERRITOS, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced the appointment of Kim Tzoumakas to its Board of Directors, effective February 23, 2026. Ms. Tzoumakas brings more than two decades of executive leadership experience across oncology, pharmacy services and healthcare operations. Notably, she is Chief Executive Officer for VytlOne National Pharmacy Services, and previously held the CEO role at 21st Century Oncology, where she successfully led the organization through a multi-year operational turnaround, culminating in its strategic sale. She also has serve

    2/23/26 8:00:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    The Oncology Institute Announces Resignation of Board Member Gabe Ling

    CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise. "On behalf of the Board of Directors, I want to thank Gabe for his service during an important chapter in The Oncology Institute's development," said Anne McGeorge, Chairman of the Board. "We appreciate the contributions he made throughout his time on the Board and the valua

    12/1/25 8:30:00 AM ET
    $TOI
    Medical/Nursing Services
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Financials

    Live finance-specific insights

    View All

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

    Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for t

    3/25/26 4:01:00 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

    SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. shoul

    3/18/26 8:30:00 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLR
    $AVTX
    $CARM
    $DERM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 5:35:24 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 4:00:47 PM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by NewAmsterdam Pharma Company N.V.

    SC 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)

    12/17/24 10:28:58 AM ET
    $NAMS
    Biotechnology: Pharmaceutical Preparations
    Health Care